Is it really impossible to stop taking dacomitinib/dacomitinib?

Dacomitinib (Dacomitinib), as an irreversible EGFR tyrosine kinase inhibitor, is mainly used to treat patients with epidermal growth factor receptor (EGFR) gene mutations non-small cell lung cancer (NSCLC). Since its mechanism of action is to continuously inhibit the EGFR signaling pathway to control tumor growth, regular and continuous use is required to maintain the efficacy. Many patients will be concerned about whether the medication can be stopped midway during use, especially when the condition is stable or side effects occur. In fact, dacomitinib is not "absolutely non-stop", but whether it needs to be suspended should be carefully evaluated by an oncologist based on the patient's individual condition.

If the patient stops taking the drug on his own, it may lead to rapid tumor progression. Especially if sufficient treatment cycles are not completed, the cancer cells may lose their inhibition and re-enter a state of rapid proliferation. Even if the condition is significantly relieved after treatment, the anti-tumor effect of the drug must be maintained to prevent the recurrence of minimal residual disease. Especially in some patients with clear genetic mutations and clear efficacy, long-term use can significantly extend progression-free survival.

However, if the patient experiences serious adverse reactions, such as rash, diarrhea, oral mucosal ulcers and other side effects that affect the quality of life, doctors will consider temporarily discontinuing the drug, adjusting the dose, or switching to other targeted drugs based on the severity. During the treatment process, you should closely monitor your body's reaction and maintain communication with your doctor. You should never decide to stop taking the medicine or change the way you take it.

In short, although dacomitinib needs to be taken for a long time to maintain its efficacy, "The drug cannot be stopped" is not an absolute statement. The key lies in individualized management and professional guidance.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro